microbiota transplantation
MOZAIC, an AI model designed to compare donor and recipients microbiotas, predicted the microbiota convergence after FMT with an accuracy of about 80%.
Targeting gut bacteria, their metabolites, or gut-to-brain signaling could offer new strategies to prevent or treat age-related memory decline.
The agreement covers the development and future commercialization in Europe of VOWST®, the first oral LBP approved in the United States to prevent recurrent Clostridioides difficile infection.
Targeting specific bacterial strains, rather than overall gut diversity, can help develop effective microbiota therapies.
Giovanni Marasco, University of Bologna, discusses the growing evidence that links gut microbiota dysbiosis to the pathophysiology, clinical prognosis, disease progression, and treatment response of patients with IBD.
Modifying the microbiota through a fecal transplant can be safely combined with immunotherapy in people with kidney cancer.
Effective treatment of IBD requires an approach combining tailored donors, microbiota analysis, and diet.
Future studies should have clearly defined hypotheses, adequate sample size, standardized protocols, and replication using multiple independent approaches.
Fiber can influence how well bacteria from a fecal microbiota transplant successfully settle and grow in a person’s gut.
Region-specific microbial transplants may be safer and more effective than standard fecal microbiota transplants.
